Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

U.S. Senators Seek Review for Hostile Bid on Allergan

Seven U.S. senators are asking federal regulators to review the potential impact of a hostile takeover by Valeant Pharmaceuticals International Inc. of California-based Allergan Inc., the maker of Botox.

Allergan’s board has rejected a $54 billion tender offer from Valeant, which is based in Laval, Quebec. The Democratic senators wrote to the Federal Trade Commission and the Department of Justice on June 25, asking whether the deal might reduce both competition and research in certain markets. They also questioned the possible effect on drug prices. The signers included Dianne Feinstein of California, Christopher Coons of Delaware and Robert Menendez of New Jersey.

The letter cited “a growing trend in the pharmaceutical industry whereby companies make acquisitions, eliminate drug pipelines, slash R&D budgets, and arbitrage location headquarters in order to lower effective tax rates.”

In battling the takeover, Allergan has said Valeant’s offers undervalue the U.S. company.

Valeant has raised its bid twice, before making the tender offer. It is joined in its bid by Bill Ackman’s hedge fund, Pershing Square Capital Management LP., which owns 9.7 percent of Allergan’s shares and seeks to oust Allergan directors in a special meeting they are planning to hold before the year ends.

Allergan increased about 1 percent to close at $170.55 in New York. Valeant rose less than 1 percent to $126.50.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.